Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Thoracic NeoplasmsLung NeoplasmsLung Diseases
Interventions
DRUG

Teniposide administration

Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.

Trial Locations (1)

200331

Shanghai Pulmonary Hospital, Shanghai, China, Shanghai

All Listed Sponsors
collaborator

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD

UNKNOWN

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER